OVERVIEW: OUTPATIENT INFECTIONS
Slide 48 of 94
Go to slide:
1: OBJECTIVES
2: (Untitled)
3: (Untitled)
4: (Untitled)
5: (Untitled)
6: (Untitled)
7: (Untitled)
8: A PUBLIC HEALTH PROBLEM
9: (Untitled)
10: (Untitled)
11: (Untitled)
12: (Untitled)
13: RECENT & FUTURE CATEGORIES
14: (Untitled)
15: (Untitled)
16: (Untitled)
17: (Untitled)
18: (Untitled)
19: (Untitled)
20: (Untitled)
21: (Untitled)
22: (Untitled)
23: (Untitled)
24: (Untitled)
25: ANTIBIOTICS
26: ANTIBIOTICS
27: (Untitled)
28: (Untitled)
29: (Untitled)
30: PENICILLINS
31: PENICILLINS
32: PENICILLINS
33: (Untitled)
34: (Untitled)
35: (Untitled)
36: (Untitled)
37: (Untitled)
38: (Untitled)
39: CEPHALOSPORINS
40: CEPHALOSPORINS
41: CEPHALOSPORINS
42: (Untitled)
43: (Untitled)
44: (Untitled)
45: (Untitled)
46: NOSOCOMIAL SEPTICEMIA
47: (Untitled)
48: OVERVIEW: OUTPATIENT INFECTIONS
49: (Untitled)
50: LOWER RESPIRATORY INFECTIONS
51: LOWER RESPIRATORY INFECTIONS
52: RENEWED INTEREST IN NON-BETA LACTAMS
53: (Untitled)
54: STREPTOGRAMINS
55: (Untitled)
56: OXAZOLIDINONES
57: (Untitled)
58: (Untitled)
59: (Untitled)
60: (Untitled)
61: (Untitled)
62: (Untitled)
63: (Untitled)
64: (Untitled)
65: (Untitled)
66: (Untitled)
67: (Untitled)
68: (Untitled)
69: QUINOLONES
70: (Untitled)
71: QUINOLONES
72: (Untitled)
73: FLUOROQUINOLONES
74: FLUOROQUINOLONES
75: FLUOROQUINOLONES
76: (Untitled)
77: (Untitled)
78: (Untitled)
79: MACROLIDES
80: MACROLIDES
81: (Untitled)
82: (Untitled)
83: CLARITHROMYCIN
84: (Untitled)
85: AZITHROMYCIN
86: AZITHROMYCIN
87: AZITHROMYCIN
88: KETOLIDES
89: (Untitled)
90: (Untitled)
91: (Untitled)
92: (Untitled)
93: (Untitled)
94: (Untitled)
